? FLOW CYTOMETRY SHARED RESOURCE (FCSR) Flow cytometry services are critical for cancer research. Since flow cytometry instrumentation is expensive, and typically requires significant technical expertise, a centralized resource is essential. The mission of the FCSR is to support OSUCCC members and high-impact cancer research projects with high quality cell analysis and sorting capabilities. The FCSR also provides training and regularly host technology-based seminars or workshops to introduce new technology to OSUCCC members. The FCSR continues to strive to be a state-of- the-art cell analysis laboratory that has the following Specific Aims to: 1) provide state-of-the-art equipment and support for high-quality cancer research for OSUCCC members on a fee-for-service basis; 2) continuously work with OSUCCC members to provide substantial technical expertise and training for state-of the-art cytometry instruments to address fundamental questions in cancer research so that researchers can have 24-hour access to flow cytometry instrumentation; and 3) introduce OSUCCC members to new instrumentation, technology and methodologies being developed at the FCSR through a variety of educational outreach activities. The FCSR co- Directors are Jeffrey Chalmers, (Department of Chemical and Biomolecular Engineering), and recently appointed co-Director, Kevin Weller, Associate Director of the Pelotonia Institute of Immuno-Oncology (PIIO) and specifically to develop the Immune Monitoring and Discovery Platform, a cross-cutting shared-resource initiative that integrates shared resources for complex immuno-oncology projects. Further, Dr. Gregory Behbehani (LR) is a Faculty Advisor for the Helios mass cytometer (CyTOF) system. Over the current grant cycle, major changes to the FCSR were to align with the establishment of the PIIO, which will result in a substantial increase in the need for flow cytometry services. To address this need, new instrumentation was purchased including four new instruments including a state-of-the-art Cytek Aurora flow cytometer and a Helios mass cytometer. During this time period, the FCSR contributed to 231 publications (39 >10 impact factor), had 296 users with 34,118 hours of service (83.7% to OSUCCC members), and supported 80 NCI grants (1 K12, 1 K22, 1 K24, 6 P01s, 1 P50, 52 R01s, 1 R03, 7 R21s, 3 R35s, 1 R37, 1 T32, and 5 U01s). In the next funding cycle, the FCSR will support the increasing needs of all OSUCCC strategic priorities, including immuno-oncology, translational genomics, cancer engineering, and cancer prevention and survivorship. The user base will substantially increased requiring new staff and technologies, for example by purchasing an additional Aurora instrument, and increasing cell sorting, cell isolation, and exosome/microvesicle research. In addition, new services under development include development of further exosome characterization and isolation technology. The annual budget of the FCSR is $518,075, yet the CCSG request is $108,261. As such, the FCSR leverages extensive institutional support and seeks only 20.9% support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090010
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Salzer, Wanda L; Burke, Michael J; Devidas, Meenakshi et al. (2018) Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. Cancer 124:1150-1159
Yu, Peter Y; Lopez, Gonzalo; Braggio, Danielle et al. (2018) miR-133a function in the pathogenesis of dedifferentiated liposarcoma. Cancer Cell Int 18:89
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545
Sprague, Leslee; Lee, Joel M; Hutzen, Brian J et al. (2018) High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. Viruses 10:
Nakashima, Hiroshi; Alayo, Quazim A; Penaloza-MacMaster, Pablo et al. (2018) Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep 8:208
Coss, Christopher C; Clinton, Steven K; Phelps, Mitch A (2018) Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy? Clin Cancer Res 24:5787-5789
Rogers, Kerry A; Huang, Ying; Ruppert, Amy S et al. (2018) Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood 132:1568-1572
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348
Burton, Jenna H; Mazcko, Christina; LeBlanc, Amy et al. (2018) NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. Clin Cancer Res 24:5830-5840
Presser, Brynne E; Katz, Mira L; Shoben, Abigail B et al. (2018) Effects of an Education Intervention about HPV Self-Testing for Healthcare Providers and Staff. J Cancer Educ 33:954-959

Showing the most recent 10 out of 2602 publications